Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-16
2005-08-16
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
51, 51, C544S162000, C562S431000, C562S450000, C564S169000
Reexamination Certificate
active
06930106
ABSTRACT:
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
REFERENCES:
patent: 5552426 (1996-09-01), Lunn et al.
patent: 6177551 (2001-01-01), Kasina
patent: 6307087 (2001-10-01), Buchwald et al.
patent: 6703379 (2004-03-01), Iino et al.
patent: 6777442 (2004-08-01), Haning et al.
patent: WO 98/33501 (1998-08-01), None
patent: WO 00/06529 (2000-02-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 01/77091 (2001-10-01), None
patent: WO 02/04425 (2002-01-01), None
Amatore, C., “Role of dba in the Reactivity of Palladium (0) Complexes Generated in Situ from Mixtures of Pd(dba)2and Phosphines,”Coordination Chemistry Reviews,1998, 511-528, vol. 178-180.
Baudoin, O., “Cyclobisintercaland Macrocycles: Synthesis and Physiochemical Properties of Macrocyclic Polyamines Containing Two Crescent-Shaped Dibenzophenanthroline Subunits,”Journal of Organic Chemistry, 1997, 5458-5470, vol. 62.
Behrens, et al., “Identification and Properties of the RNA-dependent RNA Polymerase of Hepatitis C. Virus,”EMBO J, 1996, 12-22, vol. 15, No. 1.
Berg, et al., Pharmaceutical Salts,Journal of Pharmaceutical Sciences, 1977, 1-19, vol. 66, No. 1.
Black, D. S.,Aust. Journal Chem., 1983, 2395-2406, vol. 36, No. 12.
Bourson, J., “Synthèse et Oxydo-rèduction des Sels de Diphènyl-1,3 Benzimidazolium,”J., Bull. Soc. Chim, Fr., 1970, 1867-1872, No. 5.
Buchwald, et al., “An Improved Catalyst System for Aromatic Carbon Nitrogen Bond Formation: The Possible Inveolvement of Bis(Phosphine) Palladium complexes as Key Intermediates,”J. Amer. Chem. Soc., 1996, 7215-7216, vol. 118.
Buchwald, et al., “A Highly Active Catalyst for the Room-Temperature Amination and Suzuki Coupling of Aryl Chlorides,”Angew. Chem. Int. Ed., 1999, 2413-2416, vol. 38, No. 16.
Buchwald, et al., “Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides,”Journal of Organic Chemistry, 2000, 1144-1157, vol. 65.
Buchwald, et al., “Palladium-catalyzed Amination of Aryl Halides and Sulfonates,”Journal of Organometallic Chemistry, 1999, 125-146.
Ebisawa, et al., “Retinoid X Receptor-Antagonistic Dizzepinylbenzoic Acids,”Chem. Pharm Bull., 1999, 1778-1786, vol. 47, No. 12.
Ferrari, et al., “Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed inEscherichia coli,” Journal of Virology, 1999, 1649-1654, vol. 73, No. 2.
Hartwig, et al., A Second-Generation Catalyst for Aryl Hailide Amination: Mixed Secondary Amlines from Aryl Halides and Primary Amines Catalyzed by (DPPF) PdCl2, J. Amer. Chem Soc., 1996, 7217-7218, vol. 118.
Hartwig, et al., “Discrete High Molecular Weight Triarylamine Dendrimers Prepared by Palladium-Catalyzed Amination,”J. Amer. Chem Soc., 1997, 11695-11696, vol. 119.
Hartwig, et al.,“Palladiium-Catalyzed C-Nsp2) Bond Formation: N-Arylation of Aromoatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes,”J. Amer. Chem Soc., 1998, 827-828, vol. 120.
Houghton, M.,Hepatitis C Viruses Fields Virology, 1996, 1035-1058, Third Edition, Edited by B. N. Fields, Kippincott-Raven Publishers, Philadelphia, PA.
Ishido, et al., “Complex Formation of NS5B and NS4A Proteins of Hepatitis C Virus,”Biochemical and Biophysical Research Communications, 1998, 35-40, vol. 244.
Kato, et al., “Molecular Cloning of the Human Hepatitis C Virus Genome from Japanese Patients with Non-A, Non-B Hepatitis,”Proc. Natl. Acad. Sci. USA, 1990, 9524-9528, vol. 87.
Lau, et al., “Application of Six Hepatitis C Virus Genotyping Systems to Sera from Chronic Hepatitis C Patients in the United States,”The Journal of Infectious Diseases, 1995, 281-289, vol. 171, No. 2.
Lohmann, et al., “/Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity,”Journal of Virology, 1997, 8416-8428, vol. 71, No. 11.
March, et al.,Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 2001, 5thEdition, Wiley-Interscience.
Nagar, et al.,Proc. Natl. Acad. Sci. India, Section A, 1993, 617-622, vol. 63, No. 4.
Umemiya, et al., “Regulation of Retinoidal Actions by Diazepinylbenzoic Acids.1Retinoid Synergists Which Activate the RXR-RAR Heterodimers,”Journal of Medicinal Chemistry, 1997, 4222-4234, vol. 40.
Van Doorn, L. J., “Review: Molecular Biology of the Hepatitis C Virus,”Journal of Medical Virology, 1994, 345-356, vol. 43.
Webster, et al., “HCV Genotypes-Role in Pathogenesis of Disease and Response to Therapy,”Balliere's Clinical Gastroenterology, 2000, 229-240, vol. 14, No. 2.
Wuts & Greene,Protective Groups in Organic Synthesis, Wiley-Interscience, New York, USA.
Finzel Barry Craig
Funk Lee A.
Kelly Robert Charles
Reding Matthew T.
Wicnienski Nancy Anne
Lambkin Deborah C.
Pharmacia & UpJohn Company
Richardson Peter C.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
Inhibitors of HCV NS5B polymerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of HCV NS5B polymerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of HCV NS5B polymerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3451921